Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX versus QOLIANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX versus QOLIANA.
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX vs QOLIANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist; chlorpheniramine is a histamine H1 receptor antagonist.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
5 mL (hydrocodone 10 mg/chlorpheniramine 8 mg) orally every 12 hours; maximum 10 mL (20 mg hydrocodone/16 mg chlorpheniramine) per 24 hours.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
None Documented
None Documented
Hydrocodone: 3.8-6 hours (extended-release formulation may have biphasic elimination). Chlorpheniramine: 21-27 hours. Clinical context: Steady-state reached in 2-5 days for chlorpheniramine.
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Renal excretion: hydrocodone primarily as conjugates and unchanged drug (~60%), chlorpheniramine primarily as metabolites (~80% renal). Fecal excretion: minimal (<10%).
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Category D/X
Category C
Opioid Agonist
Opioid Agonist